npj Parkinson s DiseaseNeurosciencePeer-reviewed journal article
Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson's disease
Cheryl E. G. LeynsiD, Alice PrigentiD, Brenna BeezholdiD, Lihang Yao, Nathan Galen HatcheriD, Peining Tao, John J. KangiD, EunRan R. SuhiD, Vivianna M. Van DeerliniD, John Q. TrojanowskiiD, Virginia M.‐Y. LeeiD, Matthew E KennedyiD, Matthew J. Fell, Michael X. HendersoniD
Abstract
Parkinsons disease (PD) and dementia with Lewy bodies (DLB) are progressive neurodegenerative diseases characterized by the accumulation of misfolded -synuclein in the form of Lewy pathology. While most cases are sporadic, there are rare genetic mutations that cause disease and more common variants that increase incidence of disease. The most prominent genetic mutations for PD and DLB are in the GBA1 and LRRK2 genes. GBA1 mutations are associated with decreased glucocerebrosidase activity and lysosomal accumulation of its lipid substrates, glucosylceramide and glucosylsphingosine. Previous studies have shown a link between this enzyme and lipids even in sporadic PD. However, it is unclear how the protein pathologies of disease are related to enzyme activity and glycosphingolipid levels. To address this gap in knowledge, we examined quantitative protein pathology, glucocerebrosidase activity and lipid substrates in parallel from 4 regions of 91 brains with no neurological disease, idiopathic, GBA1-linked, or LRRK2-linked PD and DLB. We find that several biomarkers are altered with respect to mutation and disease severity. We found mild association of glucocerebrosidase activity with disease, but a strong association of glucosylsphingosine with -synuclein pathology, irrespective of genetic mutation. This association suggests that Lewy pathology precipitates changes in lipid levels related to disease severity.
- organism: human
- assay: proteomics
- research focus: differential expression
- research focus: protein structure prediction
- approach: statistical model
- Citations
- 39
- FWCI
- 6.89
- Field percentile
- top 2%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Shared and Distinct Lipid Profiles in amygdala from Sporadic and GBA-associated Parkinson's Diseases
Sonia Sanz Muñoz, Frederik Ravnkilde Marlet, … Céline Galvagnion·npj Parkinson s DiseasePeer-reviewed·May 11, 2026
- Neuronopathic GBA1 L444P mutation accelerates glucosylsphingosine levels and formation of hippocampal alpha-synuclein inclusions
Casey L. Mahoney-Crane, Megha Viswanathan, … Laura A. Volpicelli‐Daley·Journal of NeurosciencePeer-reviewed·Dec 7, 2022
- Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation
C. Galvagnion, S. Cerri, … D. A. Di Monte·bioRxiv·Nov 9, 2020
- CSF glucosylsphingosine is a central readout of GCase impairment across genetic and sporadic Parkinson’s disease
Jillian H. Kluss, Di Jiang, … Sarah Huntwork·bioRxiv·Jun 22, 2026
- GALC variants affect Glucocerebrosidase to Galactosylceramidase activity ratio
Amirhossein Rajabi Vajargah, Konstantin A. Senkevich, … Ziv Gan‐Or·medRxiv·Oct 7, 2026
- The activities of LRRK2 and GCase are positively correlated in clinical biospecimens and experimental models of Parkinson's disease
Maria Kedariti, Emanuele Frattini, … Nicoletta Plotegher·npj Parkinson s DiseasePeer-reviewed·Jul 19, 2022